ACADIA Pharmaceuticals Inc ACAD:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
35.78 -0.54   -1.49%--969,5971.3M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/23/2017 (03:59 PM 10/23/2017 Eastern Standard Time)

Latest News Headlines for ACADIA Pharmaceuticals Inc

Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs News Commentary PALM BEACH, Florida, October 18, 2017 /PRNewswire/ -- Biotech Briefing: The Biotech Sector continues to impress and even surprise many as the SPDR S&P Biotech ETF (XBI) has surged 49 percent in 2017 to its highest level in more than two years and some industry professionals believe the climb isn't over just yet. Erin Gibbs, a portfolio manager with S&P Global, stands by the fact the "the average stock in the XBI is trading at 21 percent below its [average] analyst target price. The average stock is rated a buy." The health care sector in general has enjoyed a strong year this year, up 20 percent since January, as many biotechs have the attention of Wall Street ahead of the third-quarter earnings season such as: Moleculin Biotech, Inc. (NASDAQ: MBRX), AmpliPhi Biosciences Corporation (NYSE: APHB), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), Abeona Therapeutics Inc. (NASDAQ: ABEO), Acadia Pharmaceuticals Inc. (NASDAQ: ACAD).

View more recent headlines

Peers Information HelpACAD ACADIA Pharmaceuticals Inc vs. Peers

ACADIA Pharmaceuticals Inc
FibroGen Inc
Juno Therapeutics Inc
Clovis Oncology Inc
Sarepta Therapeutics Inc
ACADIA Pharmaceuticals Inc
FibroGen Inc
Juno Therapeutics Inc
Clovis Oncology Inc
Sarepta Therapeutics Inc
ACADIA Pharmaceuticals Inc
FibroGen Inc
Juno Therapeutics Inc
Clovis Oncology Inc
Sarepta Therapeutics Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open36.49
Previous Close35.78
Day High36.88
Day Low35.77
52 Week High10/5/2017 | 41.20
52 Week Low11/3/2016 | 20.68
% Off 52 Week High-13.16%
% Off 52 Week Low73.02%
Beta (5 Yr)3.7
Volatility Avg10/23/2017 | 49.23
10-Day Avg. Volume1,308,377
Market data is delayed by at least 15 minutes.

expand, down-facing arrow indicating expanded view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2017 | -2.53
P/E Ratio6/30/2017 | --
Market CapMid Cap | 4.38B
Shares Outstanding122.40M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short6.51M
Short Ratio6.2
Short % of Float5.33%
As of 9/29/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.